CoronaryAtlas logo
CoronaryAtlas
acylcarnitines
Pathway / Myocardial injury (shared endpoint)

acylcarnitines

metabolite

Acylcarnitines accumulate during ischemic myocardial injury reflecting impaired fatty-acid oxidation and energy metabolism.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleMetabolomic signature of myocardial ischemia and metabolic perturbation in acute MI.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
39
C — confounder / Type-II
71
A — assay feasibility
42
E — evidence strength
26
T1DI (composite)
4
Specificity differential (R−C)-32
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(8)